ArticlePloS one2026
Unraveling the significance of decorin in endometriosis development through single cell sequencing and experimental approaches.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA link exists between decorin (DCN) and endometriosis, nevertheless, the role of DCN in this condition remains unclear. This study aims to bioinformatically characterize DCN expression, diagnostic value, and related signaling in endometriosis using single-cell and bulk transcriptomic data, with experimental validation of expression level.
methodsSingle-cell RNA sequencing (scRNA-seq) was analyzed using Scissor and ROGUE algorithms to identify key cell types associated with endometriosis. CIBERSORTx was used to construct a signature matrix for deconvolution of bulk RNA-seq data and estimation of immune and stromal subpopulation proportions. DCN expression was explored across datasets and validated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in endometrial and endometriotic stromal cells. Its diagnostic value was assessed by receiver operating characteristic (ROC) curve analysis, and associated pathways were predicted by gene set enrichment analysis (GSEA). Potential DCN-targeted drugs were predicted via bioinformatic databases.
resultsStromal cells were identified as the key cell type with high heterogeneity and dominant DCN expression. Ten stromal subtypes were delineated, with Activated/Myofibroblast-like Stromal Cells (AMSC), Fibrosis-Effector Stromal Cells (FESC), Stemness-Remodeling Stromal Cells (SRSC), and dStromal showing significantly altered proportions in endometriosis. DCN was significantly upregulated in endometriosis at both transcriptomic and cellular levels, with area under the curve (AUC) > 0.8 in two independent datasets, supporting its diagnostic potential. GSEA indicated DCN correlates with complement/coagulation cascades, TGF-β signaling, and other pathways linked to tissue remodeling and inflammation. Seven candidate drugs targeting DCN were predicted as hypothesis-generating leads.
conclusionThis study provides bioinformatic and correlative evidence that DCN is abnormally upregulated in endometriotic stromal cells and exhibits favorable diagnostic value. DCN is associated with pathways relevant to endometriosis pathogenesis and represents a promising biomarker and therapeutic candidate pending future functional and mechanistic validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.